EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference...

* Reuters is not responsible for the content in this press release.

Tue Jul 7, 2009 9:00am EDT 

EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The
International Conference on Alzheimer's Disease

WATERTOWN, Mass., July 7 /PRNewswire/ -- 

    WHAT:           EnVivo Pharmaceuticals to share results from its Ib/IIa
                    trial in Alzheimer's disease patients with its
                    nicotinic alpha-7 agonist EVP-6124.

    WHEN:           Wednesday, July 15, 2009.

    WHERE:          Alzheimer's Association 2009 International Conference
                    on Alzheimer's Disease (ICAD) in Vienna, Austria.

    WHO:            Dana Hilt, MD, senior vice president, clinical
                    development and chief medical officer, EnVivo
                    Pharmaceuticals.

    ADDITIONAL:     EVP-6124 is EnVivo's novel alpha-7 nicotinic
                    acetylcholine receptor agonist currently in development
                    for Alzheimer's disease and cognitive dysfunction
                    associated with schizophrenia.  In this trial, safety
                    and effects on cognition of EVP-6124 were tested in
                    Alzheimer's patients already on long term treatment
                    with acetylcholine esterase inhibitors.


About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical
company dedicated to discovering and developing small molecule therapeutics
for disorders of the central nervous system, with a current focus on
Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead
product is an alpha-7 nicotinic acetylcholine receptor agonist and has been
tested in Phase 2a clinical trials for cognition disorders in Alzheimer's
disease and Schizophrenia. The company's other programs include an epigenetics
program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the
lead molecule for cognition in Alzheimer's disease which is in Phase 1
studies, and several preclinical programs such as a Gamma Secretase Modulator
(for Alzheimer's disease) and a PDE10 inhibitor program (for Schizophrenia).
For more information about EnVivo, visit www.envivopharma.com.


SOURCE  EnVivo Pharmaceuticals

Michael Aalto, Media Relations for EnVivo Pharmaceuticals, +1-617-563-9462
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.